Adlai Nortye Group Ltd. revenue

Adlai Nortye Group Ltd.'s revenue was $5.0m in fiscal 2025, up 0.0% on the year before.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Adlai Nortye Group Ltd.: revenue history, annual
Fiscal year	2021Dec 2021	2023Dec 2023	2025Dec 2025
Revenue	46	5	5
Growth on the year before	—	−89.1%	0.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Adlai Nortye Group Ltd.	$5.0m	—	—
Inventiva S.a.	$5.1m	-49.1%	—
Rani Therapeutics Holdings, Inc.	$4.9m	306.4%	—
Immuron Ltd	$5.2m	10.9%	—
Bolt Biotherapeutics, Inc.	$4.7m	12.8%	—
Entrada Therapeutics, Inc.	$4.7m	-94.1%	—

Compare with peers

Head to head: ANL vs IVA ANL vs RANI ANL vs IMRN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Adlai Nortye Group Ltd.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Adlai Nortye Group Ltd.